Takeda said that study data shows that Actos can have a positive effect on several measures of cardiovascular disease outcomes in high-risk patients with type two diabetes.
In the study, the incidence of recurrent stroke was reduced by 47% and the combined risk of death, heart attack, or stroke was reduced by 28% in patients who received Actos.
“Because they are at higher risk, it is important to find solutions that impact not only glycemic control but overall cardiovascular health. These findings show the potential benefits Actos can have in managing diabetes and the risk factors that contribute to cardiovascular disease,” said Dr Robert Spanheimer, senior medical director for diabetes and metabolism at Takeda Pharmaceuticals.